Vikas Vikram Singh*

Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA

*Corresponding Author: Vikas Vikram Singh, Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA.

Received: January 11, 2022; Published: February 01, 2022

Chimeric antigen receptor T (CAR-T) cell is a novel class of immunotherapy that involves genetically manipulating immune cells derived from the patient to better recognize tumor antigen. This cell-based gene therapy has become the standard of care in some hematological malignancies including pediatric acute lymphoblastic leukemia and for certain types of Non-Hodgkin lymphomas. Three kinds of CAR-T cell therapies, Kymriah, Yescarta were approved for clinical application in 2017, and Tecartus was approved in 2020, while several others are still under the clinical trial phase. These approved therapies target CD19, a surface antigen, found on B cells. CAR-T cells have existed since the late 1980s but over the years the design has become more complex and more effective as our knowledge of how the immune system functions have expanded.

Citation

Citation: Vikas Vikram Singh. “CAR-T Cell Immunotherapy: Hopes and Challenges for Cancer Treatment". Acta Scientific Microbiology 5.3 (2022): 01-02.

Copyright

Copyright: © 2022 Vikas Vikram Singh. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.